Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review)

The chimeric antigen receptor (CAR) is an artificially modified fusion protein consisting of an extracellular antigen-binding domain, transmembrane domain and intracellular signalling domain. CAR-T therapy has demonstrated remarkable clinical efficacy in hematological malignancies. However, cytokine release syndrome and other side effects have hindered its application in solid tumors. CAR-natural killer (NK) cells have attracted broad attention due to their safety in clinical applications, their mechanism in recognising cancer cells and the abundance of its clinical specimens. Preclinical and clinical trials of human primary NK cells and NK-92 cell lines demonstrated that CAR-NK cells are able to fight haematological malignancies and solid tumors. However, the implication of CAR-NK cell therapy also has certain challenges, including the expansion and activation of primary NK cells in vitro, selection of CAR targets, survival time of CAR-NK cells in vivo, storage and transportation of NK cells, and efficiency of NK cell transduction. This review focuses on the latest progress of CAR-NK cells in the treatment of solid tumors.

[1]  Lijun Xu,et al.  Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer , 2020, Frontiers in Immunology.

[2]  P. Thall,et al.  Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.

[3]  A. Flores,et al.  Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652 , 2020, Expert opinion on therapeutic patents.

[4]  U. Mansmann,et al.  Systemic antitumor effect by regional hyperthermia combined with low-dose chemotherapy and immunologic correlates in an adolescent patient with rhabdomyosarcoma – a case report , 2020, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[5]  Shu Wang,et al.  CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts , 2019, Molecular therapy oncolytics.

[6]  Chunyan Liu,et al.  Availability of NK cell expansion agent combined with recombinant IL‑2 and IL‑15 stimulation on the expansion and high‑purity of NK cells in patients with immune‑related pancytopenia in vitro. , 2019, Molecular medicine reports.

[7]  R. Sékaly,et al.  Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells , 2019, Scientific Reports.

[8]  Zhen-xi Zhang,et al.  Role of NKG2D and its ligands in cancer immunotherapy. , 2019, American journal of cancer research.

[9]  Jin-hai Tang,et al.  Future perspectives of Sleeping Beauty transposon system in cancer research , 2019, EBioMedicine.

[10]  U. Kontny,et al.  Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells , 2019, Translational oncology.

[11]  M. Aricò,et al.  2B4 dysfunction in XLP1 NK cells: More than inability to control EBV infection. , 2019, Clinical immunology.

[12]  Yan Sun,et al.  Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Junsang Doh,et al.  Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21 , 2019, Front. Immunol..

[14]  L. Chicaybam,et al.  CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo. , 2019, Human gene therapy.

[15]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  O. Galibin,et al.  Ex vivo Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer , 2019, Front. Immunol..

[17]  W. Murphy,et al.  NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell. , 2018, The Journal of clinical investigation.

[18]  I. Nakagawa,et al.  Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells , 2018, AntiCancer Research.

[19]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[20]  Seung Woo Park,et al.  In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model , 2018, In Vivo.

[21]  Charles H. Yoon,et al.  Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity , 2018, Science.

[22]  P. Parham,et al.  Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. , 2018, Blood.

[23]  J. Orange,et al.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.

[24]  G. Lal,et al.  The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy , 2017, Front. Immunol..

[25]  Z. Tian,et al.  Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy , 2017, Acta Pharmacologica Sinica.

[26]  Z. Tian,et al.  Developmental and Functional Control of Natural Killer Cells by Cytokines , 2017, Front. Immunol..

[27]  Z. Tian,et al.  NK cell-based immunotherapy for cancer. , 2017, Seminars in immunology.

[28]  S. Carotta.  Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches , 2016, Front. Immunol..

[29]  W. Wels,et al.  NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[30]  G. Konjević,et al.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies , 2016, Immunologic research.

[31]  Peter Bader,et al.  Selection and expansion of natural killer cells for NK cell-based immunotherapy , 2016, Cancer Immunology, Immunotherapy.

[32]  H. Kohrt,et al.  Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy , 2015, Front. Immunol..

[33]  R. Germain,et al.  NK-DC crosstalk controls the autopathogenic Th17 response through an innate IFN-γ–IL-27 axis , 2015, The Journal of experimental medicine.

[34]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[35]  I. Pastan,et al.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1&agr;-secreting Glioblastoma , 2015, Journal of immunotherapy.

[36]  G. Cao,et al.  Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers , 2015, Cancer biology & therapy.

[37]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[38]  D. Campana,et al.  A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. , 2013, Cancer research.

[39]  Elaine Coustan-Smith,et al.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.

[40]  S. Rosenberg,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[41]  W. Wels,et al.  NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin , 2012, Journal of cellular and molecular medicine.

[42]  W. Wels,et al.  Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor , 2012, Cancer Immunology, Immunotherapy.

[43]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[44]  S. Rosenberg,et al.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Lewis L Lanier,et al.  Up on the tightrope: natural killer cell activation and inhibition , 2008, Nature Immunology.

[46]  F. Bushman,et al.  DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer , 2008, Nucleic acids research.

[47]  W. Yokoyama,et al.  How do natural killer cells find self to achieve tolerance? , 2006, Immunity.

[48]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[49]  Ying K. Tam,et al.  Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. , 2001, Journal of hematotherapy & stem cell research.

[50]  V. Pathak,et al.  Design of retroviral vectors and helper cells for gene therapy. , 2000, Pharmacological reviews.

[51]  P Parham,et al.  Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. , 1997, Immunity.

[52]  L. Glimcher,et al.  Identification of a cell-surface antigen selectively expressed on the natural killer cell , 1977, The Journal of experimental medicine.

[53]  Depei Wu,et al.  First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. , 2018, American journal of cancer research.

[54]  Sang-Ki Kim,et al.  Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells. , 2016, Methods in molecular biology.

[55]  Annette Oxenius,et al.  NK cells regulating T cell responses: mechanisms and outcome. , 2015, Trends in immunology.

[56]  Lewis L Lanier,et al.  Natural killer cells and cancer. , 2003, Advances in cancer research.